4 completed, 3 terminated, 1 unknown, 1 withdrawn. 9 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 8 | Completed 4, Terminated 2, Unknown 1, Withdrawn 1 |
Follow veltuzumab: new trials by email Literature Review of veltuzumab trials Research Report on veltuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis Veltuzumab - Rheumatoid Arthritis | Phase 2 | Terminated | Takeda | 300 | 2011-08-01 | 2016-04-13 |
| Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma 90Y-epratuzumab tetraxetan, veltuzumab - Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Weill Medical College of Cornell University | 4 | 2010-10-01 | 2018-02-22 |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab - Non Hodgkin's Lymphoma, NHL | Phase 1 / Phase 2 | Withdrawn | Gilead Sciences | 2010-05-01 | 2021-08-18 | |
| Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) humanised monoclonal antibody, veltuzumab, humanised monoclonal antibody epratuzumab, humanised monoclonal antibodies veltuzumab and epratuzumab - Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | Phase 1 / Phase 2 | Unknown | Queen Mary University of London | 55 | 2010-01-01 | 2014-07-14 |
| Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma milatuzumab, veltuzumab, Correlative/Special Studies - Lymphoma | Phase 1 / Phase 2 | Completed | Beth Christian | 35 | 2009-09-01 | 2017-02-06 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
| Study of Veltuzumab (hA20) at Different Doses in Patients With ITP veltuzumab - Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 48 | 2007-11-01 | 2021-08-16 |
| Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma hA20-humanized anti-CD20 antibody - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Gilead Sciences | 82 | 2004-09-01 | 2021-08-17 |
| Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma veltuzumab - Non-Hodgkin's Lymphoma, Lymphoma, Diffuse | Phase 1 / Phase 2 | Completed | Gilead Sciences | 39 | 2004-03-01 | 2021-08-18 |
Lymphoma, Follicular (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Arthritis, Rheumatoid (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Gilead Sciences (5) · Beth Christian (1) · Queen Mary University of London (1) · Takeda (1) · Weill Medical College of Cornell University (1)
United States (7) · United Kingdom (3) · Argentina (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Mexico (1) · Poland (1) · Spain (1)
William Wegener, MD, PhD (4) · Beth Christian, MD (1) · Matthew Smith, Doctor (1) · Peter Martin, MD (1) · William Wegener, MD, PHD (1)
PMID 19451441, PMID 21173095, PMID 23829485, PMID 25847298, PMID 26389849, PMID 27515248